Elevation Pharmaceuticals

Elevation Pharmaceuticals’ COPD trial shows positive results

Tuesday, September 27, 2011

Elevation Pharmaceuticals, a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, has reported positive results from a phase IIa study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The results demonstrated a statistically significant and well-tolerated improvement in lung function over the 24-hour time period post dosing for EP-101 versus placebo. EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an optimized, Investigational eFlowR Nebulizer System (PARI Pharma GmbH).

[Read More]